黄芪注射液对中晚期NSCLC患者化疗后骨髓系统和肿瘤标志物的影响  

Effects of Huangqi Injection on Bone Marrow System and Tumor Markers in Patients with Middle-advanced Stage Non-small-cell Lung Cancer after Chemotherapy

作　　者：王荣华 马良赟[1] 廖泽飞[1] 张乐 王耿杰[1] Wang Ronghua;Ma Liangyun;Liao Zefei;Zhang Le;Wang Gengjie(Department of Thoracic Surgery,The 180th Hospital of PLA,Quanzhou 362000,China)

机构地区：[1]中国人民解放军第180医院胸外科,泉州362000

出　　处：《世界中医药》2018年第11期2795-2799,共5页World Chinese Medicine

基　　金：泉州市科技计划项目(2012z66)

摘　　要：目的:探讨黄芪注射液对中晚期非小细胞肺癌(NSCLC)患者化疗后骨髓系统和肿瘤标志物的影响。方法:选取2016年2月至2017年4月中国人民解放军第180医院收治的中晚期NSCLC患者75例,按随机数字表法随机分为对照组(n=37)和观察组(n=38)。2组患者均进行化疗,21 d为1个周期,共化疗4个周期,观察组在每个化疗周期的前15 d进行黄芪注射液静脉滴注,1次/d,共治疗4个周期。检测2组患者化疗前后全血T细胞亚群变化、骨髓抑制情况、血清肿瘤标志物水平;化疗4个周期后统计2组临床疗效。结果:与化疗前比,化疗1～4个周期后2组全血CD3+、CD4+比例及观察组CD4+/CD8+呈先降低后升高趋势(P <0. 05或P <0. 01),且化疗2、4个周期后观察组显著高于对照组(P <0. 01); 2组全血CD8+较化疗前呈先升高后降低的趋势,且化疗2、4个周期后观察组显著低于对照组(P <0. 01);与化疗前比,化疗4个周期后2组全血白细胞计数、血小板计数、血红蛋白水平及中性粒细胞计数显著降低(P <0. 01),且对照组显著低于观察组(P <0. 01);与化疗前比,化疗4个周期后2组血清CEA、CA-50、CYFRA21-1水平显著降低,且观察组显著低于对照组(P <0. 01);化疗4个周期后观察组ORR为71. 05%,显著高于对照组的40. 54%(P <0. 05)。结论:黄芪注射液可显著改善中晚期NSCLC患者化疗后免疫状态及骨髓系统,降低其肿瘤标志物水平,提高化疗疗效。Objective：To explore the effects of Huangqi Injection on bone marrow system and tumor markers in patients with middie-advanced stage non-small-cell lung cancer （NSCLC） after chemotherapy. Methods ：A total of 75 patients with middle-advanced stage NSCLC admitted to The 180th Hospital of PLA from February 2016 to April 2017 were selected and divided randomly into control group （n = 37） and observation group （n = 38） according to random number table method. The patients of 2 groups re- ceived chemotherapy for four 21 -day courses. The observation group was given intravenous injection of Huangqi Injection at the first 15 days of each chemotherapy course （1 time/d） , and it was continuously treated for 4 courses. The whole blood T cell subsets, bone marrow inhibition and serum tumor markers levels were detected before and after chemotherapy; the clinical efficacy in 2 groups were statistically analyzed after 4 courses of chemotherapy. Results： Compared with before chemotherapy, the whole blood CD3^＋ , CD4^＋ ratio in 2 groups and CD4^＋/CD8^＋ in observation group showed a trend of decreasing first and then increasing after 1-4 courses of chemotherapy （P 〈 0. 05 or P 〈 0. 01 ） ; and observation group was significantly higher than control group after 2-4 courses of chemotherapy （P 〈 0. 01 ） ; the whole blood CD8^＋ ratio in the two groups showed a trend of increasing first and then decreasing （P 〈 0. 01 ） , and observation group was significantly lower than control group after 2-4 courses of chemotherapy （P 〈 0. 01 ）. Compared with before chemotherapy, the serum leukocyte count, platelet count, hemoglobin level and neutrophil count in 2 groups after 4 courses of chemotherapy significantly decreased （ P 〈 0. 05 or P 〈 0. 01 ） , and observation group was significantly lower than control group （P 〈0. 01 ）. Compared with before chemotherapy, serum CEA, CA-50 and CYFRA21-1 levels in 2 groups after 4 courses of chemotherapy significantly decreased, and obser

关 键 词：中晚期非小细胞肺癌 化疗 黄芪注射液 骨髓系统 肿瘤标志物 

分 类 号：R273[医药卫生—中西医结合]